Enanta Pharma's NASH drug meets mid-stage study goal

Enanta Pharmaceuticals Inc said on Wednesday its drug to treat non-alcoholic steatohepatitis (NASH) met the main goal of reducing levels of elevated liver enzymes in a mid-stage study.